Cosciens Biopharma Inc 's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Cosciens Biopharma Inc 's ROA in the fourth quarter of 2025?
Cosciens Biopharma Inc recorded a cumulative net loss of $-10 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -40.05%.

However, within the Consumer Non Cyclical sector 174 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4577.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	-44.18 %	-45.98 %	-46.79 %	246.47 %	33.23 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-10	-23	-27	-26	-24
Return On Assets (TTM)	-40.05 %	-78.02 %	-78.21 %	-63.57 %	-67.13 %
CSCI's Total Ranking	# 4577	#	#	#	# 4721
Total Assets (TTM) in million	21	23	28	31	38
Seq. Total Assets Change	-8.06 %	-15.41 %	-11.51 %	-18.89 %	-11.02 %
Seq. Net Income Change	-	-	-	-	-

CSCI's 5 Years Annual ROA >> Back to CSCI Management Effectiveness >> Compare CSCI ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 23
Sector	# 175
Overall	# 4537

Return On Assets Statistics
High	Average	Low
16.74 %	-16.51 %	-48.33 %
(Dec 31 2018)		(Dec 31 2025)

Financial Statements
Cosciens Biopharma Inc 's Assets	$ 21 million	CSCI's Balance sheet
Cosciens Biopharma Inc 's Income	$ -2 million	Quarterly CSCI's Income Statement
CSCI's Income by Division		See CSCI's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-38.13 %	54.76 %	44.66 %	-27.31 %	-35.05 %
Total Assets in million	24	38	25	17	24
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-10	-15	-3	3	-8
Annual Return On Assets	-43.61 %	-39.87 %	-14.05 %	20.1 %	-35.47 %

CSCI's 5 Years Annual ROA >> Back to CSCI Management Effectiveness >> Compare CSCI ROA to its Competitors

More Return On Assets Ratios
CSCI's' Return on Assets at Yahoo Finance
Personal & Household Products Industry Return On Assets Trends and Statistics
Consumer Non Cyclical Sector Roa Statistics
Roa Trends for overall market
CSCI's Roa Ratio versus Personal & Household Products Industry, Consumer Non Cyclical Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CSCI's Competitors
Subscribers only: Roa for Cosciens Biopharma Inc 's Suppliers
Subscribers only: Return On Assets for CSCI's Customers

You may also want to know
CSCI's Roi	CSCI's Inventory Turnover Ratio	CSCI's Growth Rates	CSCI's Dividend Comparisons
	CSCI's Profitability Ratios	CSCI's Asset Turnover Ratio	CSCI's Dividend Growth
CSCI's Roe	CSCI's Valuation Ratios	CSCI's Financial Strength Ratios	CSCI's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Consumer Non Cyclical Sector

ROA

Date modified: 2026-09-18T14:10:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.